Status:
COMPLETED
Are SARS-CoV-2 Specific Antibodies a Correlate for Protection?
Lead Sponsor:
Institute of Tropical Medicine, Belgium
Collaborating Sponsors:
Jessa Hospital
University Hospital, Antwerp
Conditions:
SARS-CoV2
COVID-19
Eligibility:
All Genders
18-99 years
Phase:
NA
Brief Summary
The objectives of this study are (1) to determine the ex vivo neutralizing capacity and the longevity of SARS-CoV-2-specific Ab responses and (2) to measure the memory B-cell responses in a cohort of ...
Detailed Description
SARS-CoV-2 has spread at an unprecedented speed and scale since January 2020. Since then, Belgium has been confronted with \>60.000 diagnosed cases and likely many more undiagnosed with mild or no sym...
Eligibility Criteria
Inclusion
- Be diagnosed (PCR+) with COVID-19 between March-May 2020
- Be a permanent employee (HCW: nurse, physician, paramedical) of the study hospital
- Agree to complete a short questionnaire and be sampled 4 tubes of heparin whole blood every 3 months over a one-year period
- Have given their informed consent to participate
Exclusion
- Persons in serious clinical condition, incompatible with the informed consent procedure
- Pregnant women
- Persons that have not been diagnosed with COVID-19
Key Trial Info
Start Date :
July 31 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2022
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04469634
Start Date
July 31 2020
End Date
December 31 2022
Last Update
March 6 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Antwerp
Antwerp, Belgium, 2000
2
Jessa Hospital
Hasselt, Belgium